ERBB2 and neoplasm: One of these clinically validated antibodies, trastuzumab (27), binds to the tumor-specific protein HER2 and was selected as a proof of concept to validate use of an antibody for providing localized costimulation through delivery of a costimulatory vIgD to tumor cells, rather than a toxin or other coupled entity.